Innovative Drug DeliveryMAT2203 is an application of Matinas's lipid nanocrystal (LNC) delivery that makes amphotericin available by oral administration and has demonstrated safety at high doses for sustained periods of time.

Partnership AgreementMatinas announced it entered a non-binding agreement with an undisclosed partner for global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections.

Bears Say

Financial HealthThe company lacks funds to materially advance any programs forward.

Leadership ChangesMatinas is implementing 80% workforce reduction, eliminating 15 positions, including departure of the CMO, CBO and CTO.

Strategic PartnershipPartnering negotiations for its lead asset MAT2203 were terminated by the prospective partner.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

16.51%

Insiders

1.96% Mutual Funds

1.24% Other Institutional Investors

79.14% Public Companies and Individual Investors

Detailed Ownership Overview >

MTNB FAQ

What was Matinas BioPharma’s price range in the past 12 months?

Matinas BioPharma lowest stock price was $0.47 and its highest was $9.63 in the past 12 months.

What is Matinas BioPharma’s market cap?

Matinas BioPharma’s market cap is $4.65M.

When is Matinas BioPharma’s upcoming earnings report date?

Matinas BioPharma’s upcoming earnings report date is Aug 19, 2025 which is in 60 days.

How were Matinas BioPharma’s earnings last quarter?

Matinas BioPharma released its earnings results on May 08, 2025. The company reported -$0.326 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.326.

Is Matinas BioPharma overvalued?

According to Wall Street analysts Matinas BioPharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Matinas BioPharma pay dividends?

Matinas BioPharma does not currently pay dividends.

What is Matinas BioPharma’s EPS estimate?

Matinas BioPharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Matinas BioPharma have?

Matinas BioPharma has 5,086,985 shares outstanding.

What happened to Matinas BioPharma’s price movement after its last earnings report?

Matinas BioPharma reported an EPS of -$0.326 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.408%.

Which hedge fund is a major shareholder of Matinas BioPharma?

Currently, no hedge funds are holding shares in MTNB

Company Description

Matinas BioPharma

Matinas BioPharma Holdings, Inc. (MTNB) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for the treatment of various infectious diseases and other conditions. The company's core product offerings include lipid nano-crystal (LNC) delivery technology, which enhances the bioavailability and efficacy of drugs. Matinas BioPharma is headquartered in Bedminster, New Jersey and operates primarily in the healthcare and biotechnology sectors.